Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Syntax may still be phone orders only m8..............IMHO
Apollon Formularies
@apollon_uk
·
46m
It has sign-off for everything from cultivation to extraction and production
Crucially, it has a research & development (R&D) licence that has allowed it to clinically formulate treatments for patients at its facility on the island
https://twitter.com/apollon_uk
Just wondering, will the new listing be live the day after the GM, or will it take a few weeks to implement ?
Some still holding at over 45p....................DYOR
Do the walk of shame, hope things don't change and the 3 leave, hell or the 3 I will take hell.................
It does if you are holding in the 20p to 40p range. DL has diluted this company to oblivion with nothing to show for it. Just pleased that he will no longer be involved.
Very large part of the newly issued shares will be escrowed though.
If it goes up dilution doesn't mater, if it goes down everyone is screwed
Not worried. I hold Afri
On Admission and subject to Shareholder and regulatory approval, the Company proposes to change its name to Apollon Formularies PLC
And you know who diluted us...............
Do the walk of shame..............................
Extract:
Going forward, the company is looking at potential “third-party sales agreements” for Apollon products in countries such as South Africa and Greece, says Jacobs.
Corporate developments may include ‘up listing’ here in the UK and taking a stock market quote in the US, most likely on the OTC QB.
Jacobs says the company has news flow “coming thick and fast” after the RTO
Andrew you found what I read, well done mate...................
Looking good........... LOL
Yes, basically the RTO of Apollon Formularies is going ahead and the AGM is to approve the transaction and associated placing. The good news is we get a new BOD and hopefully a route to a success.
The bad news is existing shareholders have been heavily diluted so it is going to take quite a while before the share price recovers to anywhere near current holders values.
You don't need to do anything, but on the 13th Aptril the company name will change to Apollon Formularies. Ticker:APOL
Has anyone read the AGM circular for the upcoming vote? I'm not clear how this decision affects the shares I currently hold....could somebody clarify
https://www.otcmarkets.com/
https://en.wikipedia.org/wiki/Over-the-counter_(finance)#:~:text=Over-the-counter%20%28OTC%29%20or%20off-exchange%20trading%20is%20done%20directly,transparency%2C%20and%20maintaining%20the%20current%20market%20price%20.
Going forward, the company is looking at potential “third-party sales agreements” for Apollon products in countries such as South Africa and Greece, says Jacobs.
Corporate developments may include ‘up listing’ here in the UK and taking a stock market quote in the US, most likely on the OTC QB.
Jacobs says the company has news flow “coming thick and fast” after the RTO.
Up 36 views in one hour................. :+)
44 views only..................
https://www.youtube.com/watch?v=rg4jeqKtZs4
From 20 mins in 1.2 million per day $6.00 million US per week..... £4.3 million per week ball park....
https://www.youtube.com/watch?v=Z2w5W2FEQmY
DATE
16.03.21
A full spectrum of opportunities for Apollon Formularies
“…Investors will do very well over the next five years if they invest in Apollon…”
With the plethora of cannabis-related listings across UK stock exchanges, the accessibility to consumer CBD and cannabinoid focused companies has increased and investors are holding the likes of Kanabo and Cellular Goods in their ‘green’ portfolios.
It’s less likely they are holding stock in soon-to-be listed Apollon Formularies as the book is already closed after a substantially oversubscribed fundraise.
Head of Business Development Stene Jacobs explains that a lot of capital has already been ‘sunk’ into Apollon so the company didn’t need a huge quantum, but for those who missed out “there is a second round of fundraising that will happen within 2021.”
Apollon is a full spectrum medical cannabis company which makes use of THC in its formulations. That’s the part which makes the consumer high, but more importantly it’s the key component that makes the cannabis medication work.
The only other company permissioned to use THC in its formulas and have FDA-approved prescription cannabidiol medicine is GW Pharmaceuticals which has been bought by Jazz Pharmaceuticals for $7.2 billion.
In addition to its CBD product range, Apollon too includes THC in its medical formulations and has federally approved licences which include its coveted R&D licence which gives it a legal route to conducting physician-supervised human treatments. The company has already done so on close to 500 patients with what Jacobs describes as “phenomenal results.”
Bringing the company to the Aquis Exchange via a reverse takeover is founder and physician Dr. Stephen Barnhill aka ‘The Doc.’ He migrated from producing medicine for big pharma to what at the time was the more niche cannabis treatments that he engaged with when his mother became unwell.
Guiding him through the listing process is Rod McIlree who at the age of 29 years was the youngest person to list a company on the ASX. McIlree has launched multiple companies since then and is currently chairman of Bluejay Mining. (JAY.L)
Listen to Stene talk to Sarah Lowther about the company’s USP’s, how 3D printing will revolutionise medication delivery, its unique-in-the-world R&D licence which allows Apollon to use formulations on patients and the altruism that will be the founder’s swan song and a money maker for investors.
In case anyone missed.................
Buying interest27 Oct '20
I can probably shed some light on this folks. The company has been generating some interest amongst subscribers to the Michael Walters investment site in the past few days, where there is a new thread relating to this company. Changes are expected imminently which may revive it's fortunes. I myself listened in on an investment call hosted by Dr Barnhill of Apollon only last week, along with CEO of another well-known AIM company (not DL). Sorry but MW is a paid forum so I cannot divulge and you would have to subscribe if you want to read up more on what is currently being discussed. It's well worth the money if you do, not just because of the thread on AgriAg.
Apollon is a medical cannabis company based in Jamaica, where it holds a suite of licences and is fully regulated, allowing the company to work with full spectrum oils inclusive of THC. The company plans, using its own formulations, to develop medicines for conditions that afflict humans in the modern world.
It aims to create a globally recognised brand synonymous with quality, consistent potency on a range of products for a range of conditions withing the medical cannabis space.
Apollon Formularies will through its subsidiary Apollon Formularies Jamaica Ltd (a fully licensed full spectrum medical cannabis company), develop, market, distribute and sell full spectrum (inclusive of THC) products in the legal hemp and medical cannabis industry. It is currently producing pharmaceutical, nutraceutical and other medical cannabis related products, including 3D printed sublingual, suppositories and capsules. Apollon Formularies was established to advance the current significant commercial opportunities in the legal medical cannabis markets globally.
Apollon Formularies Jamaica Limited (“AFJ”) is licensed to operate at the Federal level in Jamaica and hold the following licences and approvals:
Medically supervised treatments
Cultivate cannabis
Retail dispensary license
Retail therapeutic distribution
Extraction processing facility
“Tier 3” conditional cultivation approval expected soon
Licences include R&D using THC
Together these licences create a vertically integrated full spectrum (inclusive of THC) medical cannabis company both in Jamaica and to the international market via legal export from Jamaica to countries where the law allows import of medical cannabis products.
https://www.apollon.org.uk/about